Visioneering Technologies Inc.

A clear path forward.  Correct Astigmatism up to 3.00 D while managing myopia. You no longer have to choose between correcting astigmatism and managing myopia. The latest study data shows that NaturalVue Multifocal demonstrates proven astigmatism correction of 83% up to 3.00 D and 100% up to 2.00 D. SEE THE recently published article: https://qrco.de/bftaF7 MKT-MM-SM1

Correct Astigmatism up to 3.00 D while managing myopia. Good news for your myopic patients with astigmatism! New data from our clinical study shows proven astigmatism correction of 83% up to 3.00 D and 100% up to 2.00 D. Now you no longer have to choose between correcting astigmatism and managing myopia. Study link in comments.

https://lnkd.in/eh_VQZ4Y Congrats!

NEWS: New Data Affecting Myopic Astigmatic Patients: NaturalVue Multifocal demonstrates 100% astigmatic correction up to 2.00 D and 83% to 3.00 D Press Release: https://ow.ly/IlvM50UIIcW

NEWS: Visioneering Announces Positive Interim 2-Year Data for their NaturalVue® Multifocal 1 Day Contact Lens from the PROTECT Multi-center, Randomized, Double-Masked Clinical Trial for Myopia Progression Control Press Release: https://ow.ly/v6aO50UIGCm

VTI is thrilled to announce that NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses, in partnership with our Authorized Distributor Positive Impact, has won The Contact Lens Award at the prestigious Optician Awards!   The Optician Awards celebrates excellence within the UK optical industry. With a legacy spanning over 30 years, these awards are among the most esteemed recognitions in British optics. The winners were unveiled on November 22 in London. MKT-VTI-PR89

I’m so pleased that Visioneering Technologies Inc. and it’s NaturalVue 1-Day Multifocal lens has finally got the recognition it deserves at this year’s Optician Awards 👏 This year’s submission was built around the PROTECT RCT data that clearly demonstrates the fantastic #myopiacontrol efficacy of this unique lens design. There surely can’t be any better cause than this in #optometry at this time… That it can also deliver better vision for many #presbyopes than zonal multifocals, especially when they have a high add, is a brilliant bonus! I’d like to say congratulations to all the other winners, not forgetting all those shortlisted. In particular well done to Ultravision, the only other company to make the shortlist the #contactlens award. Our experience with this award is if at first you don’t succeed try, try again! Finally thanks to Lyndon Jones Nick Dash Brian Tompkins Craig McArthur Bhavin Shah, MCOptom, DipTP (IP),FBCLA, MBABO for their support with this nomination and fitting of this amazing contact lens. 🙏

Don’t miss out on the opportunity to attend the Joint Scientific Program/Residents Poster Session on November 8, 1-3 PM in Exhibit Hall H! 🪧 Check out the VTI posters at Academy 2024: • Board 66: “A Unique Multifocal Contact Lens Design Provides Functional Vision for All Presbyopes” - What you’ll learn: See how a contact lens can be a unicorn for presbyopes • Board 74: “Patient Reported Outcomes in a Randomized Controlled Myopia Progression Study (PROTECT) of a Soft Multifocal Contact Lens” - What you’ll learn: - Data confirms happy kids - No noticeable vision compromise - No comfort compromise - Outstanding Year-1 treatment effect The VTI team also welcomes you to Booth #230 to learn how NaturalVue® (etafilcon A) Enhanced Multifocal 1 Day contact lenses accommodate a range of myopic and presbyopic patients. We look forward to connecting with you in Indianapolis! #Academy24 #PROTECT #NaturalVue #Myopia #VTI VTI-RCT-SM11

Breaking News: Data confirms that kids are happy in NaturalVue Multifocal and it works for Myopia Management Curious to explore these exciting breakthroughs further? Join VTI and Chief Medical Officer, Dr. Kuang-mon (Ashley) Tuan for a new-data presentation at Academy 2024. • Session Title: “Just Released: New learnings from the PROTECT Clinical Trial in addition to how NaturalVue Multifocal manages myopia in children” • When: November 8, 8-8:45 AM • Location: JW Marriott in White River A You can expect to hear new insights from the PROTECT MPC Clinical Trial, including: • Pupil size treatment implications, especially relevant for children spending time outdoors • Clinically relevant adjusted treatment effect (equalized for age, sex, pupil size, site, factors that may influence myopic progression) • Children’s subjective responses on quality of life • The lens’ impact on binocular vision #Academy24 #PROTECT #NaturalVue #Myopia #VTI VTI-RCT-SM11

Just In: NaturalVue Multifocal Delivers 89% (or 0.48 D) Reduction in Refractive Error Progression* Want to hear more groundbreaking findings? Join us for another exclusive presentation by VTI’s Chief Medical Officer, Dr. Kuang-mon (Ashley) Tuan. • Session Title: “Just Released: New learnings from the PROTECT Clinical Trial in addition to how NaturalVue Multifocal manages myopia in children”  • When: November 8, 8-8:45 AM  • Location: JW Marriott in White River A #Academy24 #PROTECT #NaturalVue #Myopia #VTI *Adjusted treatment effect (vs. Control) equalized for age, sex, pupil size, site, factors that may influence myopic progression.